Serotonergic function and suicidal behavior in schizophrenia

被引:27
作者
Corrêa, H
Duval, F
Mokrani, MC
Bailey, P
Trémeau, F
Staner, L
Diep, TS
Crocq, MA
Macher, JP
机构
[1] Univ Fed Minas Gerais, Dept Pharmacol, Inst Ciencias Biol, BR-31280901 Belo Horizonte, MG, Brazil
[2] Ctr Hosp Rouffach, F-68250 Rouffach, France
[3] Inst Res Neurosci & Psychiat, F-68250 Rouffach, France
关键词
schizophrenia; suicide; D-fenfluramine; serotonergic; function;
D O I
10.1016/S0920-9964(01)00181-5
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Recent studies suggest that altered serotonergic (5-HT) function, as assessed by lower prolactin (PRL) response to fenfluramine (FEN), a specific 5-HT releaser and uptake inhibitor, is associated with suicidal behavior in either depressed and personality disordered patients. The purpose of this study was to investigate, in schizophrenic patients, the relationship between suicidal behavior and PRL response to D-fenfluramine (D-FEN). A D-FEN test was performed in 18 healthy controls and 33 drug-free DSM-IV schizophrenic patients (12 with a history of suicide attempts, 21 without it). Schizophrenic patients with a history of suicide attempts showed a lower PRL response to D-FEN (DeltaPRL) compared to schizophrenic patients without such history (P < 0.04) and also compared to healthy controls (P < 0.0003). DeltaPRL did not differentiate schizophrenic patients without suicide attempts and controls. These findings could not be explained by PRL basal hormonal levels, age, sex, menstrual status, demographic or clinical characteristics. These results suggest that PRL response to D-FEN is a marker of suicidality also in schizophrenia, supporting the hypothesis that a dysfunction in serotonergic function is associated with suicidal behavior regardless of the psychiatric diagnosis. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:75 / 85
页数:11
相关论文
共 76 条
[1]   Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients [J].
Abel, KM ;
OKeane, V ;
Murray, RM .
BRITISH JOURNAL OF PSYCHIATRY, 1996, 168 (01) :57-60
[2]   Serotonergic function and negative and depressive symptomatology in schizophrenia and major depression [J].
Abel, KM ;
OKeane, V ;
Murray, RM ;
Cleare, AJ .
PSYCHONEUROENDOCRINOLOGY, 1997, 22 (07) :539-548
[3]   RISK-FACTORS FOR SUICIDE AMONG PATIENTS WITH SCHIZOPHRENIA [J].
ALLEBECK, P ;
VARLA, A ;
KRISTJANSSON, E ;
WISTEDT, B .
ACTA PSYCHIATRICA SCANDINAVICA, 1987, 76 (04) :414-419
[4]   SCHIZOPHRENIA - A LIFE-SHORTENING DISEASE [J].
ALLEBECK, P .
SCHIZOPHRENIA BULLETIN, 1989, 15 (01) :81-89
[5]  
ASBERG M, 1976, ARCH GEN PSYCHIAT, V33, P1193
[6]  
Asberg M, 1981, Adv Exp Med Biol, V133, P739
[7]  
Beautrais AL, 1996, AM J PSYCHIAT, V153, P1009
[8]  
BECK AT, 1975, AM J PSYCHIAT, V132, P285
[9]  
Brent DA, 1996, ARCH GEN PSYCHIAT, V53, P1145
[10]   AGGRESSION IN HUMANS CORRELATES WITH CEREBROSPINAL-FLUID AMINE METABOLITES [J].
BROWN, GL ;
GOODWIN, FK ;
BALLENGER, JC ;
GOYER, PF ;
MAJOR, LF .
PSYCHIATRY RESEARCH, 1979, 1 (02) :131-139